Robert W. Baird Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $759.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective decreased by research analysts at Robert W. Baird from $940.00 to $759.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Robert W. Baird’s target price indicates a potential upside of 5.11% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. TD Cowen cut their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $722.07 on Wednesday. The firm’s 50 day simple moving average is $717.27 and its 200-day simple moving average is $914.93. Regeneron Pharmaceuticals has a 12 month low of $642.00 and a 12 month high of $1,211.20. The stock has a market capitalization of $79.35 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 1.60 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $11.86 EPS. Analysts expect that Regeneron Pharmaceuticals will post 37.75 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. One Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 2.5% during the fourth quarter. One Capital Management LLC now owns 12,486 shares of the biopharmaceutical company’s stock worth $8,894,000 after purchasing an additional 310 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $65,180,000. Cullen Frost Bankers Inc. lifted its position in shares of Regeneron Pharmaceuticals by 1,244.8% during the fourth quarter. Cullen Frost Bankers Inc. now owns 6,307 shares of the biopharmaceutical company’s stock worth $4,493,000 after purchasing an additional 5,838 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Regeneron Pharmaceuticals by 0.6% during the fourth quarter. Arizona State Retirement System now owns 31,224 shares of the biopharmaceutical company’s stock worth $22,242,000 after purchasing an additional 185 shares in the last quarter. Finally, Aigen Investment Management LP lifted its position in shares of Regeneron Pharmaceuticals by 780.6% during the fourth quarter. Aigen Investment Management LP now owns 6,367 shares of the biopharmaceutical company’s stock worth $4,535,000 after purchasing an additional 5,644 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.